{"id":12871,"date":"2024-09-08T12:19:47","date_gmt":"2024-09-08T10:19:47","guid":{"rendered":"https:\/\/valintermed.com\/?p=12871"},"modified":"2024-09-08T12:19:47","modified_gmt":"2024-09-08T10:19:47","slug":"distrofiya-glaznogo-dna-sorsbi","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/","title":{"rendered":"Sorsby&#039;s fundus dystrophy"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Sorsby fundus dystrophy, also known as hereditary retinal dystrophy, is a rare genetic disorder characterized by progressive destruction of the macular area of the retina. This leads to impairment of central vision, which significantly affects the quality of life of patients. The disease manifests itself in the form of various signs, including pinpoint protrusions, swelling of the retinal layers, and the development of neovascularization. As the dystrophy progresses, special cells of the retina - photosensitive receptors responsible for the perception of light and colors - are damaged. Without timely diagnosis and adequate treatment, the dystrophy can lead to significant vision loss.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\" >Genetic predisposition to this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of medications used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Disease monitoring<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Age-related features of the disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/ocular-dna-dystrophy-sorsbi\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The history of Sorsby&#039;s fundus dystrophy dates back to the mid-20th century, when the disease was first described and thoroughly studied. In 1966, when the disease was first identified as a separate nosological entity, the attention of the medical community was focused on its hereditary nature and clinical manifestations. Studies based on pedigrees of families showed that the disease is inherited according to relatively simple Mendelian patterns. One of the interesting facts is that despite the rarity of the disease, it attracted the attention of geneticists, which contributed to the study of mutations in certain genes, such as RPE65 and ELOVL4, which were associated with retinal dystrophy and other pathologies.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\"><\/span>Epidemiology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sorsby fundus dystrophy is a rare disease, and various epidemiological studies estimate its prevalence to be between 1 and 4 cases per 100,000 population. It is important to note that the epidemiology of this disease varies by region and ethnic group. Scientists have found that some populations, such as those in Northern Europe, may have a higher incidence than others. In addition, studies have shown that Sorsby fundus dystrophy is more common in males than females, which also raises questions about the possible influence of sex chromosomes on the development of the disease.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\"><\/span>Genetic predisposition to this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Genetic predisposition to Sorsby&#039;s fundus dystrophy is clearly associated with mutations in certain genes, the most well-known of which are RPE65, ELOVL4 and CRB1. Mutations in these genes lead to disruptions in the metabolism of retinal cells, which in turn causes degeneration of cellular structures. For example, the RPE65 mutation is responsible for pigment metabolism in retinal pigment epithelial cells, which is critical for the restoration of visual pigments after their activation. In addition, recent studies indicate that the influence of epigenetic factors such as DNA methylation and histone modification may also play a role in regulating the expression of these genes in patients.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the risk factors for Sorsby&#039;s fundus dystrophy, the following can be distinguished:<\/p>\n<ul>\n<li>Genetic predisposition: Having relatives with retinal diseases significantly increases the risk.<\/li>\n<li>Gender: According to existing data, men are more susceptible to the disease.<\/li>\n<li>Exposure to ultraviolet radiation: Long-term unprotected sun exposure may contribute to retinal diseases, but a link to Sorsby has not been established.<\/li>\n<li>Bad habits: Factors such as smoking and drinking alcohol can aggravate the condition of the retina.<\/li>\n<li>Age: Many cases of the disease occur in older adults, although genetic factors can lead to the disease appearing at a younger age.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnosis of Sorsby&#039;s fundus dystrophy requires a comprehensive approach, which includes:<\/p>\n<ul>\n<li>Main symptoms: deterioration of central vision, presence of metamorphopsia, changes in color perception, appearance of \u201cflies\u201d before the eyes.<\/li>\n<li>Laboratory tests: genetic testing for mutations in the relevant genes.<\/li>\n<li>Radiological examinations: optical coherence tomography (OCT) helps to assess the condition of the retina and identify its structural changes.<\/li>\n<li>Other types of diagnostics of the disease: fluorescein angiography to evaluate the retinal vascular system.<\/li>\n<li>Differential diagnosis: it is necessary to exclude other degenerative processes, such as retinitis pigmentosa or simple macular degeneration.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment for Sorsby&#039;s fundus dystrophy is still in development, but includes the following approaches:<\/p>\n<ul>\n<li>General treatment: Vitamin and antioxidant supplements can be used to maintain retinal health.<\/li>\n<li>Pharmacological treatment: There are currently no specific medications aimed at treating this disease, but drugs are being developed that can slow down the process of destruction.<\/li>\n<li>Surgical treatment: If neovascular glaucoma develops, laser photocoagulation may be required to prevent further deterioration of vision.<\/li>\n<li>Other treatments: Gene therapy, which is an actively researched strategy, may provide new options for correcting the genetic defects that lead to disease.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of medications used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>There are currently no specific drugs for the treatment of Sorsby&#039;s fundus dystrophy, but the following may be used in treatment:<\/p>\n<ul>\n<li>Antioxidants (eg vitamin C, vitamin E)<\/li>\n<li>Pyridoxine (vitamin B6)<\/li>\n<li>Medicines to control intraocular pressure<\/li>\n<li>Preparations for improving microcirculation<\/li>\n<li>Drugs to slow down the degeneration process<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Monitoring the condition of a patient with Sorsby&#039;s fundus dystrophy includes regular examinations by an ophthalmologist, monitoring for changes in vision, and assessing the progress of the disease. It is necessary to carry out:<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<ul>\n<li>Control stages: annual or more frequent examinations depending on the dynamics of the disease.<\/li>\n<li>Prognosis: Early diagnosis and the introduction of preventive measures can significantly slow the progression of the disease.<\/li>\n<li>Complications: cases of neovascular glaucoma development are possible, which requires additional intervention.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Age-related features of the disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sorsby&#039;s fundus dystrophy can occur in any age group, but most often the disease begins to manifest itself in people between the ages of 30 and 50. In children and adolescents, the disease may have a more aggressive course, which requires more careful monitoring and treatment. In older patients, the disease may lead to more severe vision loss and associated diseases such as cataracts or age-related macular degeneration.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>What are the main symptoms of Sorsby&#039;s fundus dystrophy?<\/strong> The main symptoms are deterioration of central vision, the presence of \u201cflies\u201d before the eyes, as well as changes in color perception.<\/li>\n<li><strong>How is Sorsby&#039;s fundus dystrophy diagnosed?<\/strong> Diagnosis includes genetic testing, OCT, fluorescein angiography and clinical examination.<\/li>\n<li><strong>Is there an effective treatment for Sorsby&#039;s fundus dystrophy?<\/strong> There is no specific treatment yet, but research is being conducted into gene therapy and the use of antioxidants.<\/li>\n<li><strong>What factors can trigger the development of the disease?<\/strong> Genetic predisposition, gender (more common in men), and age are the main risk factors.<\/li>\n<li><strong>What is the prognosis for Sorsby&#039;s fundus dystrophy?<\/strong> Prognosis depends on early diagnosis and prompt treatment; regular monitoring can slow progression.<\/li>\n<\/ul>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Sorsby&#039;s fundus dystrophy, also known as hereditary retinal dystrophy, is a rare genetic disorder characterized by the progressive destruction of the macular<\/p>","protected":false},"author":1,"featured_media":22818,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-12871","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=12871"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12871\/revisions"}],"predecessor-version":[{"id":14059,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12871\/revisions\/14059"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media\/22818"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=12871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=12871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=12871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}